Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19826418 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: FOLFIRI.3;   Drug: FOLFOX

Indicates status has not been verified in more than two years